23andMe is spinning a new business deal to expand its stance in the market. The company has plans to collaborate with biotech firm Genetech, to analyze new treatments for Parkinson’s disease.
According to the Forbes, the genetics firm received almost $10 million to initiate the project, and allowing access to its genetic data. There are possibilities of more payments, about $50 million more in the pipe line for 23andMe from Genetech. This amount will be released ones Genetech reaches its...
Also read: Blockchain Firm R3 Raises $107 Million